After years of record-breaking overdose fatalities, fentanyl-related deaths in the United States appear to be declining — a development that public health researchers and policy analysts are working to explain, with some pointing to a quiet shift in Chinese chemical exports as a contributing factor that Beijing has little incentive to advertise.
The United States has experienced one of the most devastating drug crises in its history over the past decade, with synthetic opioids — chiefly fentanyl and its analogues — driving overdose death tolls to historic highs. Now, emerging data suggests the tide may be turning, prompting a debate among experts about what, exactly, has changed.
Writing in Foreign Affairs, researchers Peter Reuter, Jonathan P. Caulkins, and Keith Humphreys argue that the causes of the apparent decline are multiple and difficult to disentangle — and that one significant factor may be deliberate Chinese action to curtail the flow of fentanyl precursor chemicals to Mexican drug cartels, even as Beijing declines to publicly acknowledge playing such a role.
A Crisis Years in the Making
Fentanyl, a synthetic opioid roughly 50 times more potent than heroin, became the dominant driver of overdose deaths in the United States through the late 2010s and early 2020s. Unlike earlier waves of the opioid epidemic — which were largely fuelled by prescription painkillers and then heroin — the fentanyl crisis was characterised by its supply chain: precursor chemicals manufactured in China, processed into finished product by Mexican cartels, and smuggled across the US southern border.
At its peak, overdose deaths involving synthetic opioids exceeded 70,000 annually in the United States, according to the Centers for Disease Control and Prevention.
What May Have Changed
The researchers identify several plausible contributors to the recent decline. Expanded access to naloxone, the overdose-reversing medication, has become more widespread across the country. Harm reduction programmes have grown in reach. Law enforcement interdiction efforts have also intensified on multiple fronts.
But the analysts suggest that supply-side disruption — particularly any reduction in the availability of Chinese-sourced precursor chemicals reaching cartel laboratories — could be among the more consequential factors, even if it is the hardest to verify. China formally scheduled fentanyl and many of its analogues in 2019 following US diplomatic pressure, but enforcement of those measures has long been questioned.
The authors note a politically awkward dynamic: if China has indeed taken steps to restrict precursor flows, it would be unlikely to publicise this, given current US-China tensions, as doing so could be read as an implicit acknowledgement of prior complicity or as a concession to Washington.
Uncertainty Remains
Not all experts are convinced the decline is yet durable or fully understood. Drug markets are adaptive, and cartels have previously shifted to alternative precursors when one supply route was disrupted. Some public health researchers caution against drawing firm conclusions from data that is still being collected and analysed.
The relative contribution of demand-side interventions — treatment, naloxone, public awareness — versus supply-side disruption also remains a subject of active debate, with implications for where future policy resources should be directed.
Analysis
Why This Matters
- Fentanyl has been the leading cause of death for Americans aged 18–49 in recent years; any sustained decline would represent a major public health turning point with implications for families, healthcare systems, and law enforcement priorities.
- The question of what drove the decline directly shapes future US drug policy: if supply disruption is key, diplomatic and enforcement strategies take precedence; if demand-side interventions are responsible, the case for treatment and harm reduction spending strengthens.
- The potential China dimension adds a layer of geopolitical complexity, intersecting with trade negotiations, diplomatic relations, and the broader US-China rivalry.
Background
The US opioid epidemic unfolded in three broad waves. The first, beginning in the late 1990s, was driven by the overprescription of pharmaceutical opioids such as OxyContin. The second wave, emerging around 2010, saw a surge in heroin use as prescription supplies tightened. The third and deadliest wave arrived around 2013 with the rise of illicitly manufactured fentanyl and its analogues, which are far cheaper to produce and exponentially more potent than heroin.
By the early 2020s, fentanyl had effectively displaced heroin in most US drug markets, often mixed into other substances without users' knowledge. This dramatically raised the risk of accidental overdose. The CDC recorded more than 80,000 synthetic opioid-involved deaths in the 12-month period ending in mid-2023.
China's role as a source of precursor chemicals became a major point of diplomatic friction between Washington and Beijing. In 2019, under significant US pressure, China placed the fentanyl class of drugs under regulatory control. However, sceptics noted that traffickers quickly adapted by sourcing alternative precursors or routing shipments through third countries, particularly India.
Key Perspectives
Public Health Researchers: Emphasise that naloxone distribution, expanded treatment access, and harm reduction programmes deserve significant credit for any decline, and that sustainable progress requires continued investment in these demand-side tools.
Geopolitical and Drug Policy Analysts (Reuter, Caulkins, Humphreys): Argue that supply-side factors — potentially including Chinese regulatory action on precursor chemicals — may be playing a larger role than is publicly acknowledged, and that this complicates straightforward policy narratives.
Critics and Sceptics: Warn that drug market adaptability means any decline could be temporary; cartels have repeatedly found workarounds to precursor restrictions, and celebrating early data risks complacency in funding treatment and prevention programmes.
What to Watch
- CDC overdose death data for 2025 and 2026, which will confirm whether the decline is sustained or a short-term fluctuation.
- US-China diplomatic exchanges on drug precursor controls, particularly whether fentanyl features in any broader trade or security negotiations.
- Reports of shifts in cartel supply chains — such as increased use of alternative precursors or new smuggling routes — which would suggest adaptive behaviour offsetting any Chinese supply-side restrictions.